



Published in final edited form as:

*Mol Imaging Biol.* 2012 December ; 14(6): 762–770. doi:10.1007/s11307-012-0551-5.

## Longitudinal PET Imaging of Doxorubicin Induced Cell Death with $^{18}\text{F}$ -Annexin V

Shuo Hu<sup>1,2</sup>, Dale O. Kiesewetter<sup>2</sup>, Lei Zhu<sup>2</sup>, Ning Guo<sup>2</sup>, Haokao Gao<sup>2</sup>, Gang Liu<sup>2,3</sup>, Naoki Hida<sup>2</sup>, Lixin Lang<sup>2</sup>, Gang Niu<sup>2,\*</sup>, and Xiaoyuan Chen<sup>2,\*</sup>

<sup>1</sup>Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha 410008, China

<sup>2</sup>Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland, 20892

<sup>3</sup>Sichuan Key Laboratory of Medical Imaging, Department of Radiology, Affiliated Hospital of North Sichuan Medical College, Nanchong 637007, China

### Abstract

**Purpose**—This study aims to apply longitudinal positron emission tomography (PET) imaging with  $^{18}\text{F}$ -Annexin V to visualize and evaluate cell death induced by doxorubicin in a human head and neck squamous cell cancer UM-SCC-22B tumor xenograft model.

**Procedures**—*In vitro* toxicity of doxorubicin to UM-SCC-22B cells was determined by a colorimetric assay. Recombinant human Annexin V protein was expressed and purified. The protein was labeled with fluorescein isothiocyanate (FITC) for fluorescence staining and  $^{18}\text{F}$  for PET imaging. Established UM-SCC-22B tumors in nude mice were treated with two doses of doxorubicin (10 mg/kg each dose) with 1 day interval. Longitudinal  $^{18}\text{F}$ -Annexin V PET was performed at 6 h, 24 h, 3 days, and 7 days after the treatment started. Following PET imaging, direct tissue biodistribution study was performed to confirm the accuracy of PET quantification.

**Results**—Two doses of doxorubicin effectively inhibited the growth of UM-SCC-22B tumors by inducing cell death including apoptosis. The cell death was clearly visualized by  $^{18}\text{F}$ -Annexin V PET. The peak tumor uptake, which was observed at day 3 after treatment started, was significantly higher than that in the untreated tumors ( $1.56 \pm 0.23$  vs.  $0.89 \pm 0.31$  %ID/g,  $p < 0.05$ ). Moreover, the tumor uptake could be blocked by co-injection of excess amount of unlabeled Annexin V protein. At day 7 after treatment, the tumor uptake of  $^{18}\text{F}$ -Annexin had returned to baseline level.

**Conclusions**— $^{18}\text{F}$ -Annexin V PET imaging is sensitive enough to allow visualization of doxorubicin induced cell death in UM-SCC-22B xenograft model. The longitudinal imaging with  $^{18}\text{F}$ -Annexin will be helpful to monitor early response to chemotherapeutic anti-cancer drugs.

### Keywords

$^{18}\text{F}$ -Annexin V; doxorubicin; apoptosis; PET; chemotherapy

---

**For Correspondence or reprint contact either of the following:** Gang Niu, Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, 9 Memorial Drive, 9/1W111, Bethesda, MD 20892. niug@mail.nih.gov, Xiaoyuan Chen, Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, 31 Center Dr, 31/1C22, Bethesda, MD 20892. shawn.chen@nih.gov.

### Conflict of Interest

The authors declare they have no conflicts of interest.

## Introduction

Most of the chemotherapy agents, including the anthracycline antibiotic doxorubicin [1], cause tumor cell death primarily by induction of apoptosis [2]. Traditionally, apoptosis can be characterized in isolated cells by *in vitro* methods including DNA laddering and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) [3]. Histological methods play an important role in confirming apoptosis if tissue can be removed from the living system by biopsy or surgery. However, the selection bias and lack of ability to monitor the dynamic process of apoptosis limit the utility of such studies in clinical applications [4]. Therefore, there has been growing interest in the use of non-invasive functional and molecular imaging techniques to observe apoptosis [5].

As the cell undergoes apoptosis, there are a number of steps in the process that may be investigated using very different imaging modalities [6]. Among them, phosphatidylserine (PS) exposure occurs very early in the apoptotic chain of events, preceding such hallmark events as nuclear condensation and DNA laddering. Moreover, PS exposure is a near-universal event in apoptosis, and it presents a very abundant target (millions of binding sites per cell) that is readily accessible on the extracellular face of the plasma membrane [7].

Annexin V, an endogenous human protein with molecular weight of 36 kDa, has a high affinity ( $k_d = 7$  nM) for PS binding [8]. Due to the high affinity for apoptotic cells, no immunogenicity, and lack of *in vivo* toxicity, Annexin V is the dominant probe to detect and image apoptosis [9, 10]. Indeed, Annexin V has been labeled with  $^{125}\text{I}$ ,  $^{123}\text{I}$ ,  $^{111}\text{In}$  and  $^{99\text{m}}\text{Tc}$  for single-photon emission computed tomography (SPECT) imaging [11, 12]. Clinical trials among patients with various tumor types demonstrated that Annexin V imaging is a promising technique to confirm the onset of apoptosis induced by chemotherapy and radiation therapy [13–15]. For example,  $^{99\text{m}}\text{Tc}$ -Annexin V scintigraphy applied to human tumors after the first course of chemotherapy showed increased tumor uptake proving that apoptosis had been initiated [16].

Compared with SPECT, positron emission tomography (PET) has the advantage that it is more sensitive and quantitative [17]. Annexin V has been labeled with positron emission radioisotopes including  $^{124}\text{I}$  [18],  $^{68}\text{Ga}$  [19] and  $^{18}\text{F}$  [20, 21] for PET imaging. It has been found that apoptosis induced by radiation therapy or chemotherapy could be distinguished with either *in vivo* imaging or *ex vivo* autoradiography [19, 20] using these agents. However, in most of the studies, only one time point imaging was performed. We hypothesized here that a longitudinal imaging at multiple time points would be helpful to reflect the dynamic nature of drug induced apoptosis.

In our previous study, we genetically engineered UM-SCC-22B human head and neck squamous cancer cells with a cyclic luciferase, an endogenous apoptosis marker. The apoptosis induced by Doxil was confirmed with multiple imaging strategies including bioluminescence imaging (BLI) and diffusion-weighted magnetic resonance imaging (DW-MRI) [22]. In this study, we applied longitudinal PET imaging to monitor the dynamics of cell death induced by doxorubicin using  $^{18}\text{F}$ -Annexin V as imaging agent.

## Materials and Methods

### Cell line and MTT assay

Human head and neck squamous cell line UM-SCC-22B was acquired from the University of Michigan [23] and cultured in Dulbecco's modified medium supplemented with 10% (v/v) heat-inactivated FBS, 100 unit/ml penicillin, and 100  $\mu\text{g}/\text{ml}$  streptomycin at 37°C in an atmosphere of 5% (v/v)  $\text{CO}_2$ .

The toxicity of doxorubicin to UM-SCC-22B cells was determined by a colorimetric assay with 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT; Sigma). All studies were performed with triplicate samples and repeated at least three times. Briefly, cells were harvested by trypsinization, resuspended in DMEM medium, and plated in a 96-well plate at 4,000 or 2,000 cells per well. After treatment with different doses of doxorubicin (ranging from 0.1 nM to 0.5  $\mu$ M) for 48 h, the culture medium was then replaced and 50  $\mu$ l of 1.0 mg/ml sterile filtered MTT was added to each well. The unreacted dye was removed after 4 h incubation and the insoluble formazan crystals were dissolved in 150  $\mu$ l of DMSO. The absorbance at 570 nm (reference wavelength: 630 nm) was measured with a Synergy II multimode microplate reader (BioTech Instruments, VT).

### Purification and conjugation of Annexin V protein

Annexin V expressing plasmid was kindly provided by Dr. Seamus J. Martin (The Smurfit Institute, Trinity College, Dublin, Ireland) and Annexin V protein was expressed and purified according to the protocol previously reported [24]. Fluorescein isothiocyanate (FITC, Sigma-Aldrich) was dissolved in anhydrous DMSO immediately before use (3  $\mu$ l at 10 mg/ml) and then added into Annexin V (500  $\mu$ g) with a molar ratio of 5:1 in 500  $\mu$ L borate buffer (20 mM, pH 8.5). The mixture was incubated and rotated at room temperature for 60 min for covalent conjugation. The unreacted dye molecules were removed by PD-10 column (GE Healthcare).

### In vitro apoptotic staining

Cells were seed in 24 well plates and treated with doxorubicin (10  $\mu$ M) for 24 h. After rinsing twice with PBS, the cells were incubated with FITC-Annexin V for 15 min at room temperature. For blocking, 200  $\mu$ g/ml of unlabeled Annexin V was added 5 min before FITC-Annexin V was added. Then Hoechst 33342 was added to the solution and incubated for another 15 min at room temperature. The cells were rinsed three times and immediately observed with a fluorescence microscope (X81, Olympus).

### Synthesis of radioactive materials

2-deoxy-2- $^{18}$ F]fluoro-D-glucose ( $^{18}$ F-FDG) was purchased from the Nuclear Pharmacy of Cardinal Health, and reconstituted with sterile saline. The average radiochemical purity of the product was 98.5% and specific activity was  $>1,000$  Ci/mmol.

*N*-succinimidyl 4- $^{18}$ F-fluorobenzoate ( $^{18}$ F-SFB) was synthesized with a modular system (Eckert & Ziegler Eurotope GmbH) as previously reported [25].  $^{18}$ F-SFB was redissolved in 10  $\mu$ l of acetonitrile and an Annexin V (100  $\mu$ g) solution in 0.1 M NaHCO<sub>3</sub> buffer was added. The reaction was incubated at room temperature for 30 min. The reaction mixture was purified with a NAP-5 size exclusion column (GE Healthcare) according to the manufacture's procedure. The component was eluted with saline to give a fraction containing  $^{18}$ F-Annexin V after the void volume of about 0.75 ml.  $^{18}$ F-Annexin V was assayed by radio-TLC for the presence of small molecule impurities ( $R_f$  of  $^{18}$ F-SFB, 0.9;  $R_f$  of  $^{18}$ F-Annexin V, 0.09). The specific activity of  $^{18}$ F-Annexin V at the end of synthesis was  $1.53 \pm 0.66$  mCi/nmol ( $n = 5$ ).

### Animal model and treatment plan

All animal studies were conducted in accordance with the principles and procedures outlined in the NRC Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee (IACUC) of the Clinical Center, National Institutes of Health. The UM-SCC-22B tumor model was generated by subcutaneous injection of  $5 \times 10^6$  cells into the right shoulder of female athymic nude mice (Harlan

Laboratories). Tumor size was monitored with digital caliper and tumor volume was calculated as  $vol = ab^2/2$ , where a is the longest diameter and b is the shortest diameter. Two weeks after inoculation, 10 mice each with a volume around 300 mm<sup>3</sup> were randomized into two groups. One group (n = 5) received 2 doses of 10 mg/kg of doxorubicin (ALZA Corporation, USA) through intravenous administration with an interval of 1 day. The control group (n = 5) received PBS only. The acute liver apoptosis model was induced by tail vein injection of 10 mg/kg of cycloheximide (Sigma-Aldrich) [26]. Three hours later, PET scans were performed with <sup>18</sup>F-Annexin V.

### PET imaging

At day 0, 6 hours, day 1, 3, and 7 after treatment initiation, PET scans were performed with the tumor-bearing mice using <sup>18</sup>F-Annexin V. Each UM-SCC-22B tumor-bearing mouse, under isoflurane anesthesia, was injected via a tail vein with 3.7 MBq (100 μCi) of <sup>18</sup>F-Annexin V. Ten-minute static scans were acquired at 0.5, 1 and 2 h after injection, respectively (n = 5/group). For blocking experiments, 500 μg of unlabeled Annexin V was coinjected with 3.7 MBq (100 μCi, around 3 μg) of <sup>18</sup>F-Annexin V, and 10-min static PET images were acquired at 60 min after injection (n = 3) with a dedicated small animal Inveon PET scanner (Preclinical Solution, Siemens). For <sup>18</sup>F-FDG scan, mice were maintained under isoflurane anesthesia during the injection, accumulation, and scanning periods and were fasted for 6 h before tracer injection. Body temperature was maintained before and during imaging using a thermostat controlled circulating warm water pad. The images were reconstructed using a two-dimensional ordered-subset expectation maximization (2D OSEM) algorithm without correction for attenuation or scattering. For each scan, regions of interest (ROIs) were drawn over the tumor and major organs using vendor software (ASI Pro 5.2.4.0) on decay-corrected whole-body coronal images. The radioactivity concentrations (accumulation) within the tumors, muscle, liver, and kidneys were obtained from mean pixel values within the multiple ROI volume and then converted to MBq/ml/min using the calibration factor determined for the Inveon PET system. These values were then divided by the administered activity to obtain (assuming a tissue density of 1 g/ml) an image-ROI-derived percent injected dose per gram (%ID/g).

### Biodistribution study

Immediately after PET imaging, the tumor-bearing mice were sacrificed and dissected. Blood, tumor, major organs, and tissues were collected and wet-weighed. The radioactivity in the wet whole tissue was measured with a γ-counter (1480 Wizard 3 gamma counter, Perkin-Elmer). The results were expressed as percentage of injected dose per gram of tissue (%ID/g). Values were expressed as mean ± SD for a group of four animals.

### Histological staining

Tumor samples were collected and sectioned after the animals were sacrificed. DNA fragmentation was analyzed by terminal deoxynucleotidyl transferase mediated dUTP nick end labeling (TUNEL) assay using a commercial kit (Maxin-Bio) according to the manufacturer's protocol. For the staining of Ki-67, frozen tumor tissue slices were fixed with cold acetone for 20 min and dried in the air for 30 min at room temperature. After blocking with 1% bovine serum albumin for 30 min, slices were incubated with rabbit anti-mouse Ki-67 antibody (1:200; BD Biosciences) and then incubated with Dylight488-conjugated goat anti-rabbit secondary antibody (1:300; Jackson ImmunoResearch Laboratories). After being washed 3 times with PBS, the slices were mounted with 4'-6-diamidino-2-phenylindole (DAPI)-containing mounting medium and observed under an epifluorescence microscope (X81; Olympus). Each experiment was performed in pairs, and the pairs were then repeated twice.

## Statistical analysis

The data were described as means  $\pm$  standard deviation. Student's *t* test was applied to compare the statistical difference among groups. *P* value  $<$  0.05 was considered statistically significant.

## Results

### Doxorubicin treatment induces apoptosis

Consistent with our previous study, UM-SCC-22B cells are sensitive to doxorubicin treatment [22]. The  $IC_{50}$  value of doxorubicin to the cells is 10  $\mu$ M after 24 h incubation (Fig. 1a). Doxorubicin also effectively inhibited the growth of the established UM-SCC-22B tumors in nude mice. After being treated with doxorubicin for 24 h, UM-SCC-22B cells were stained with FITC-Annexin V. The strong green fluorescence signal was identified on the cell membrane of the treated cells but not on the untreated cells (Fig. 1b), indicating doxorubicin treatment induced PS externalization. Besides, the fluorescent signal was effectively blocked by co-incubation with excess amount of unlabeled Annexin V. As shown in Fig. 1c, at day 7 with two doses of 10 mg/kg of doxorubicin treatment, the tumor size in the treated group was significantly smaller than that in control group ( $p <$  0.01). Some tumors in the treated group were completely cured. It has been demonstrated previously that the tumor growth inhibition was apoptosis related [22].

### $^{18}F$ -Annexin V PET imaging

After radiolabeling of Annexin V protein with  $^{18}F$ , we first applied the tracer in a well-established acute liver apoptosis model [21]. Three mice were injected with cycloheximide (10 mg/kg) to induce apoptosis in the liver before imaging. Three hours later, about 3.7 MBq of  $^{18}F$ -Annexin V was administered via tail vein for PET imaging. As shown in Fig. 2, significantly higher uptake of  $^{18}F$ -Annexin V was observed in the treated liver than in the liver of the untreated control animals. The liver of the control mice showed a tracer uptake of  $5.51 \pm 0.77$  % ID/g while the liver of the treated mice showed a tracer uptake of  $23.66 \pm 3.33$  % ID/g ( $p <$  0.001). A 4.29-fold increase was observed, which is consistent with previously reported data [27].

It is well-known that apoptosis is a dynamic process, especially in the tumor environment [6]. With the UM-SCC-22B model, we performed PET imaging at different time points following the initiation of treatment. PET images demonstrated that  $^{18}F$ -Annexin V was excreted from both hepatic and renal urinary routes, reflected by both high liver and kidney accumulations of the radioactivity. As shown in Table 1, within 2 hrs, the kidney uptake was decreased from  $19.2 \pm 10.2$  % ID/g to  $2.57 \pm 0.32$  % ID/g and liver uptake from  $10.4 \pm 3.50$  % ID/g to  $2.43 \pm 0.49$  % ID/g. Based on the major organs uptake and ratios of tumor/non-tumor, we selected 1 h time point for the quantification of longitudinal PET images.

The tumor uptake in the control group barely exceeded the background, primarily due to the high perfusion and permeability of the tumor vasculature. At baseline, the tumors showed a tracer uptake of  $0.97 \pm 0.23$  % ID/g (day 0). After treatment with doxorubicin, the tumor uptake of  $^{18}F$ -Annexin V increased with time. As early as 6 hr after therapy, a trend of increased tumor uptake was already observed in the treated group which failed to meet our requirement for statistical significance ( $p = 0.057$ ). At day 3, the treated tumors showed a tracer uptake of  $1.56 \pm 0.23$  % ID/g, which was significantly higher than control tumors ( $0.89 \pm 0.31$  % ID/g.  $p <$  0.05). At day 7 after treatment, the difference between the two groups disappeared (Fig. 3).

In order to confirm the specificity of tumor uptake of  $^{18}\text{F}$ -Annexin V, another set of mice were treated with doxorubicin with the same dose and time interval. At day 3 after treatment, animals underwent PET imaging using  $^{18}\text{F}$ -Annexin V with or without a blocking dose of unlabeled Annexin V (500  $\mu\text{g}$  per mouse). The tumor uptake of  $^{18}\text{F}$ -Annexin V was partially blocked with extra amount of unlabeled protein ( $1.98 \pm 0.26$  vs.  $1.41 \pm 0.54$  % ID/g,  $p < 0.05$ ) (Fig. 4a & b).

### $^{18}\text{F}$ -FDG PET imaging

We also performed PET imaging using  $^{18}\text{F}$ -FDG to evaluate tumor metabolism changes after doxorubicin treatment [28]. The tumors were clearly visualized on PET images and the uptake of  $^{18}\text{F}$ -FDG of control tumors was  $7.23 \pm 1.88$  %ID/g (Fig. 4c & d). At day 3 after doxorubicin treatment,  $^{18}\text{F}$ -FDG uptake decreased significantly to  $5.26 \pm 0.46$  %ID/g ( $p < 0.05$ ).

### Biodistribution of $^{18}\text{F}$ -Annexin V

In order to further confirm the PET imaging quantification, the biodistribution of  $^{18}\text{F}$ -Annexin V was evaluated in tumor-bearing nude mice immediately after PET imaging. As shown in Fig. 5, the tumor uptakes were  $1.51 \pm 0.21$ ,  $2.26 \pm 0.37$  and  $1.42 \pm 0.25$  %ID/g in the control, treated and blocked group, respectively. As shown on PET images, both liver and kidneys showed high radioactivity uptake. It is worth noting that the tracer uptake in spleen increased dramatically from  $4.17 \pm 1.53$  %ID/g in the control group to  $17.28 \pm 3.45$  %ID/g in the treatment group. After blocking, the spleen uptake decreased to  $8.32 \pm 1.90$  %ID/g. At 1 hr after tracer injection, the radioactivity in blood circulation remained relative high, with %ID/g value around 3 in all groups.

### Histological staining

At day 3 after treatment started, the treated tumors showed significant increased uptake of  $^{18}\text{F}$ -Annexin V, although the tumor size showed no apparent change. We collected tumor samples and performed Ki-67 staining to evaluate tumor proliferation and TUNEL staining to determine the DNA damage. As shown in Fig. 6a, in the control tumor sections, a relatively high percentage of cells were stained positively for Ki-67. Significantly reduced cell proliferation was observed in the doxorubicin treated tumor. A TUNEL assay is one of the traditional *in vitro* methods to characterize cell apoptosis, and TUNEL-positive nuclei confirm DNA fragmentation. Compared to the control group, the group that received 2 doses of doxorubicin treatment showed significantly more cell apoptosis (Fig. 6b).

### Discussion

The early assessment of tumor response is of tremendous, but substantially unmet, need to assist oncologists to manage the quality of patient life versus intensive chemotherapy [29, 30]. Owing to high binding affinity with PS, Annexin V has been widely used as an imaging probe for non-invasive molecular imaging of apoptosis. However, an optimal imaging time frame following initiation of treatment still needs to be determined due to the dynamic nature of apoptosis. In this preclinical study with an established tumor apoptosis model, we determined the optimal imaging time point to reflect tumor early response of tumors to doxorubicin with longitudinal PET imaging using  $^{18}\text{F}$ -Annexin V.

Annexin V could be conjugated with an average of two mole equivalents of fluorobenzoate (FBA) without decreasing its affinity for red blood cells with exposed PS. However, an average conjugation of 7.7 decreased the binding by 3-fold [31]. In this study, we used  $^{18}\text{F}$ -SFB as the prosthetic group for Annexin V labeling and the average specific activity of  $^{18}\text{F}$ -



Annexin V was  $1.53 \pm 0.66$  mCi/nmol ( $n=5$ ). Thus, on average only one FB group was present on each Annexin V protein, which will not affect its binding affinity.

The treatment and imaging schedule was presented in Fig. 1B. We treated the UM-SCC-22B tumors with two doses of doxorubicin at one day interval and imaged the mice at day 0, 6 hr, day 1, 3 and 7 after treatment started. The results showed tumor uptake of  $^{18}\text{F}$ -Annexin V increased as early as at 6 hour after therapy and peaked at day 3. It is interesting to note that the tumor size showed no significant change at day 3 after therapy started, indicating the increase of  $^{18}\text{F}$ -Annexin V uptake in tumors precedes the size change. Moreover, the cell toxicity also has been confirmed by Ki-67 staining and TUNEL staining.

It has been pointed out that Annexin V uptake by tumor cells heavily depends on the exact time after the start of chemotherapy and there might be two peaks of Annexin V uptake. One occurs early within several hours and another probably appears in 24–72 hours after the treatment [32]. However, our data demonstrated that the cell death induced by doxorubicin occurred in a different pattern. It appears that cell death in doxorubicin treated UM-SCC-22B tumors occurs very soon after treatment begins and persists for several days. Tumor growth curves showed complete eradication of several tumors by day 7.

Using apoptosis reporter gene BLI imaging, we observed strong caspase 3 activity in Doxil treated tumors at day 5 after therapy initiation [22]. Thus, we speculate that at least in the current model, the ratio of apoptotic cells among the tumor kept increasing with time within the first several days. At day 7, the treated tumor showed decreased Annexin V uptake, partially due to the removal of the majority of apoptotic and necrotic cells. However, we cannot exclude the possibility that disruption of the tumor vasculature affected the delivery of the tracer to tumor region.

When untreated, even if the tumors grow to a size around 600 to 800  $\text{mm}^3$ , there is no apparent apoptosis or necrosis, which is confirmed by both optical and PET imaging [22] (Fig. 3). It is worthy of note that UM-SCC-22B tumors are highly vascularized with high permeability [33, 34]. Consequently,  $^{18}\text{F}$ -Annexin V showed a tumor uptake of  $1.04 \pm 0.26$  %ID/g in untreated tumors, which is mostly likely attributed to the non-specific accumulation of  $^{18}\text{F}$ -Annexin V. Thus, further studies will expand to more tumor models with various vascularization and receiving different therapeutic interventions.

Besides tumors, we found that the tracer uptake in spleen increased dramatically in treated group compared with that in the control group ( $17.28 \pm 3.45$  vs.  $4.17 \pm 1.53$  %ID/g,  $p < 0.01$ ), which reflected the toxicity of doxorubicin. Increased spleen and bone marrow uptake of Annexin V has been observed in a rat model treated with cyclophosphamide [35]. One possible explanation is that doxorubicin exerted toxic effect on bone marrow and hematopoietic progenitor cells. Consequently, damaged blood cells were captured by spleen. Specific binding of  $^{18}\text{F}$ -Annexin V to those cells resulted in high radioactivity uptake in spleen. The spleen uptake could be blocked by an excess amount of unlabeled Annexin V protein, further confirming the specific binding of  $^{18}\text{F}$ -Annexin V to apoptotic cells.

Decreased  $^{18}\text{F}$ -FDG uptake in tumor at day 3 after treatment reflected the decreased tumor metabolism and growth inhibition, which was confirmed by the tumor growth curve retrospectively (Fig. 1b). With a different drug and different tumor model, we have observed different  $^{18}\text{F}$ -FDG PET imaging results. For example, contrary to these results, we have observed that  $^{18}\text{F}$ -FDG uptake increased at day 3 after paclitaxel therapy in a MDA-MB-435 tumor model resulting from inflammation and white blood cell infiltration [28].

## Conclusion

$^{18}\text{F}$ -Annexin V PET imaging allows sensitive visualization of cell death induced by doxorubicin treatment. The longitudinal imaging with  $^{18}\text{F}$ -Annexin will be helpful to monitor tumor response to chemotherapy at early stage when used alone or combined with other molecular imaging modalities.

## Acknowledgments


This project was supported by the Intramural Research Program of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH) and the International Cooperative Program of the National Science Foundation of China (NSFC) (81028009).

## References


1. Young RC, Ozols RF, Myers CE. The anthracycline antineoplastic drugs. *N Engl J Med.* 1981; 305:139–153. [PubMed: 7017406]
2. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. *Nature.* 2001; 411:342–348. [PubMed: 11357141]
3. Otsuki Y, Li Z, Shibata MA. Apoptotic detection methods--from morphology to gene. *Prog Histochem Cytochem.* 2003; 38:275–339. [PubMed: 12756893]
4. Massoud TF, Gambhir SS. Integrating noninvasive molecular imaging into molecular medicine: an evolving paradigm. *Trends Mol Med.* 2007; 13:183–191. [PubMed: 17403616]
5. Seddon BM, Workman P. The role of functional and molecular imaging in cancer drug discovery and development. *Br J Radiol.* 2003; 76(Spec No 2):S128–S138. [PubMed: 15572335]
6. Niu G, Chen X. Apoptosis imaging: beyond annexin V. *J Nucl Med.* 2010; 51:1659–1662. [PubMed: 20956479]
7. Blankenberg FG, Katsikis PD, Tait JF, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. *Proc Natl Acad Sci U S A.* 1998; 95:6349–6354. [PubMed: 9600968]
8. Tait JF, Cerqueira MD, Dewhurst TA, et al. Evaluation of annexin V as a platelet-directed thrombus targeting agent. *Thromb Res.* 1994; 75:491–501. [PubMed: 7992250]
9. Blankenberg FG, Katsikis PD, Tait JF, et al. Imaging of apoptosis (programmed cell death) with  $^{99\text{m}}\text{Tc}$  annexin V. *J Nucl Med.* 1999; 40:184–191. [PubMed: 9935075]
10. Lahorte CM, Vanderheyden JL, Steinmetz N, et al. Apoptosis-detecting radioligands: current state of the art and future perspectives. *Eur J Nucl Med Mol Imaging.* 2004; 31:887–919. [PubMed: 15138718]
11. Ohtsuki K, Akashi K, Aoka Y, et al. Technetium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis. *Eur J Nucl Med.* 1999; 26:1251–1258. [PubMed: 10541822]
12. Ke S, Wen X, Wu QP, et al. Imaging taxane-induced tumor apoptosis using PEGylated: 111In-labeled annexin V. *J Nucl Med.* 2004; 45:108–115. [PubMed: 14734682]
13. Haas RL, de Jong D, Valdes Olmos RA, et al. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. *Int J Radiat Oncol Biol Phys.* 2004; 59:782–787. [PubMed: 15183481]
14. Kurihara H, Yang DJ, Cristofanilli M, et al. Imaging and dosimetry of  $^{99\text{m}}\text{Tc}$  EC annexin V: preliminary clinical study targeting apoptosis in breast tumors. *Appl Radiat Isot.* 2008; 66:1175–1182. [PubMed: 18308577]
15. Kartachova M, Haas RL, Olmos RA, et al. In vivo imaging of apoptosis by  $^{99\text{m}}\text{Tc}$ -Annexin V scintigraphy: visual analysis in relation to treatment response. *Radiother Oncol.* 2004; 72:333–339. [PubMed: 15450733]
16. Belhocine T, Steinmetz N, Hustinx R, et al. Increased uptake of the apoptosis-imaging agent ( $^{99\text{m}}\text{Tc}$ ) recombinant human Annexin V in human tumors after one course of chemotherapy as a




- predictor of tumor response and patient prognosis. *Clin Cancer Res.* 2002; 8:2766–2774. [PubMed: 12231515]
17. Niu G, Cai W, Chen X. Molecular imaging of human epidermal growth factor receptor 2 (HER-2) expression. *Front Biosci.* 2008; 13:790–805. [PubMed: 17981588]
  18. Glaser M, Collingridge DR, Aboagye EO, et al. Iodine-124 labelled annexin-V as a potential radiotracer to study apoptosis using positron emission tomography. *Appl Radiat Isot.* 2003; 58:55–62. [PubMed: 12485664]
  19. Bauwens M, De Saint-Hubert M, Devos E, et al. Site-specific  $^{68}\text{Ga}$ -labeled Annexin A5 as a PET imaging agent for apoptosis. *Nucl Med Biol.* 2011; 38:381–392. [PubMed: 21492787]
  20. Murakami Y, Takamatsu H, Taki J, et al.  $^{18}\text{F}$ -labelled annexin V: a PET tracer for apoptosis imaging. *Eur J Nucl Med Mol Imaging.* 2004; 31:469–474. [PubMed: 14666384]
  21. Yagle KJ, Eary JF, Tait JF, et al. Evaluation of  $^{18}\text{F}$ -annexin V as a PET imaging agent in an animal model of apoptosis. *J Nucl Med.* 2005; 46:658–666. [PubMed: 15809489]
  22. Zhang F, Zhu L, Liu G, et al. Multimodality imaging of tumor response to doxil. *Theranostics.* 2011; 1:302–309. [PubMed: 21772927]
  23. Carey TE, Van Dyke DL, Worsham MJ, et al. Characterization of human laryngeal primary and metastatic squamous cell carcinoma cell lines UM-SCC-17A and UM-SCC-17B. *Cancer Res.* 1989; 49:6098–6107. [PubMed: 2790823]
  24. Logue SE, Elgendy M, Martin SJ. Expression, purification and use of recombinant annexin V for the detection of apoptotic cells. *Nat Protoc.* 2009; 4:1383–1395. [PubMed: 19730422]
  25. Jacobson O, Weiss ID, Kiesewetter DO, et al. PET of tumor CXCR4 expression with 4- $^{18}\text{F}$ -T140. *J Nucl Med.* 2010; 51:1796–1804. [PubMed: 20956475]
  26. Beer AJ, Kessler H, Wester HJ, et al. PET imaging of integrin  $\alpha\text{v}\beta3$  expression. *Theranostics.* 2011; 1:48–57. [PubMed: 21547152]
  27. De Saint-Hubert M, Mottaghy FM, Vunckx K, et al. Site-specific labeling of 'second generation' annexin V with  $^{99\text{m}}\text{Tc}(\text{CO})_3$  for improved imaging of apoptosis in vivo. *Bioorg Med Chem.* 2010; 18:1356–1363. [PubMed: 20053567]
  28. Sun X, Yan Y, Liu S, et al.  $^{18}\text{F}$ -FPPRGD2 and  $^{18}\text{F}$ -FDG PET of response to Abraxane therapy. *J Nucl Med.* 2010; 52:140–146. [PubMed: 21149494]
  29. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst.* 2000; 92:205–216. [PubMed: 10655437]
  30. Green AM, Steinmetz ND. Monitoring apoptosis in real time. *Cancer J.* 2002; 8:82–92. [PubMed: 1199952]
  31. Grierson JR, Yagle KJ, Eary JF, et al. Production of  $^{18}\text{F}$ -fluoroannexin for imaging apoptosis with PET. *Bioconjug Chem.* 2004; 15:373–379. [PubMed: 15025534]
  32. Blankenberg F. To scan or not to scan, it is a question of timing: technetium-99m-annexin V radionuclide imaging assessment of treatment efficacy after one course of chemotherapy. *Clin Cancer Res.* 2002; 8:2757–2758. [PubMed: 12231512]
  33. Niu G, Li Z, Xie J, et al. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. *J Nucl Med.* 2009; 50:1116–1123. [PubMed: 19525473]
  34. Niu G, Sun X, Cao Q, et al. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. *Clin Cancer Res.* 2010; 16:2095–2105. [PubMed: 20215534]
  35. Blankenberg FG, Naumovski L, Tait JF, et al. Imaging cyclophosphamide-induced intramedullary apoptosis in rats using  $^{99\text{m}}\text{Tc}$ -radiolabeled annexin V. *J Nucl Med.* 2001; 42:309–316. [PubMed: 11216531]




**Fig. 1.** Doxorubicin treatment induces apoptosis in UM-SCVC-22B cells and tumors. **a** Cytotoxicity of doxorubicin on UM-SCC-22B cells determined by MTT assay. The  $IC_{50}$  is determined as 10  $\mu$ M after 24 hr incubation. **b** Fluorescence staining of UM-SCC-22B cells with FITC-Annexin V (green) after treatment with doxorubicin for 24 hr. The cells were co-stained with Hoechst 33342 (blue) for nuclei presentation. **c** The growth of UM-SCC-22B tumors was effectively inhibited by doxorubicin. The black arrows indicate the time for the two doses of doxorubicin (10 mg/kg for each dose). The green arrows indicate the time for PET imaging studies using  $^{18}F$ -Annexin V.




**Fig. 2.** Small animal PET imaging of liver apoptosis. **a** Typical decay-corrected whole-body coronal images are shown with liver indicated by white arrows. The acute liver apoptosis model was established by i.v. injection of cycloheximide (CXM, 10 mg/kg). **b** Liver uptake of  $^{18}\text{F}$ -Annexin V was quantified from PET scans ( $n = 3$ ). CXM treated mice show significantly higher liver uptake of  $^{18}\text{F}$ -Annexin V than untreated mice ( $p < 0.001$ ).



**Fig. 3.**  $^{18}\text{F}$ -Annexin V PET imaging of UM-SCC-22B tumor bearing mice with or without doxorubicin treatment. **a** Representative decay corrected whole body coronal PET images at different time points after treatment started are shown.  $^{18}\text{F}$ -Annexin V (3.7 MBq, 100  $\mu\text{Ci}$ ) was injected via tail vein and ten-minute static scans were acquired at 1 h after injection. Tumors are indicated by arrows. **b** Tumor uptake of  $^{18}\text{F}$ -Annexin V was quantified from PET scans ( $n=5$ ). After doxorubicin treatment, tumor uptake increased to a peak at day 3 after treatment started ( $p < 0.05$ ).




**Fig. 4.**  
**a** Representative decay corrected whole body coronal PET images at day 3 after treatment started.  $^{18}\text{F}$ -Annexin V (3.7 MBq, 100  $\mu\text{Ci}$ , around 3  $\mu\text{g}$ ) was injected via tail vein and ten-minute static scans were acquired at 1 h after injection ( $n=5$ ). For blocking experiments, 500  $\mu\text{g}$  of unlabeled Annexin V was coinjected with 3.7 MBq (100  $\mu\text{Ci}$ ) of  $^{18}\text{F}$ -Annexin V ( $n=3$ ). Tumors were indicated with arrows. **b** Tumor uptake of  $^{18}\text{F}$ -Annexin V was quantified by PET images. With excess unlabeled Annexin V, the tumor uptake of  $^{18}\text{F}$ -Annexin V could be blocked ( $p < 0.05$ ). **c & d** PET imaging of doxorubicin treated UM-SCC-22B tumor bearing mice at day 3 after treatment started using  $^{18}\text{F}$ -FDG. The mice were maintained under isoflurane anesthesia during the injection, accumulation, and scanning periods and were fasted for 6 h before tracer injection.  $^{18}\text{F}$ -FDG uptake in doxorubicin treated tumors was significantly lower than that in control tumors ( $n=5$ ,  $p < 0.05$ ).



**Fig. 5.** Biodistribution of  $^{18}\text{F}$ -Annexin V at 1 hr after injection in UM-SCC-22B tumor bearing nude mice. The mice have been treated with 2 doses of doxorubicin with 10 mg/kg for each dose. At day 3 after treatment started, mice were injected intravenously with 3.7 MBq (100  $\mu\text{Ci}$ ) of  $^{18}\text{F}$ -Annexin V alone (n=5) or with 500  $\mu\text{g}$  of unlabeled Annexin V (n=3). Data are presented as mean %ID/g  $\pm$  SD.





**Fig. 6.** Histologic analysis of tumor response to doxorubicin. **a** Proliferation of UM-SCC-22B tumor cells at day 3 after doxorubicin treatment as assessed by Ki-67 immunofluorescence staining. Ki-67 are shown in green. Normal cell nuclei are shown in blue, stained by DAPI. **b** TUNEL staining of UM-SCC-22B tumor section after treatment with doxorubicin. Apoptotic nuclei are shown in green. Normal cell nuclei are shown in blue, stained by DAPI.

**Table 1**

Decay-corrected in vivo distribution of  $^{18}\text{F}$ -Annexin V in UM-SCC-22B tumor bearing mice quantified by PET imaging (n = 9).

Organ	30 min	60 min	120 min
Kidneys	19.2 ± 10.2	7.57 ± 3.08	2.57 ± 0.32
Liver	10.4 ± 3.50	5.23 ± 2.37	2.43 ± 0.49
Blood *	2.98 ± 0.56	1.77 ± 0.46	0.85 ± 0.12
Tumor	1.52 ± 0.31	1.04 ± 0.26	0.59 ± 0.08
Muscle	0.69 ± 0.17	0.52 ± 0.24	0.23 ± 0.06
T/K	0.09 ± 0.03	0.15 ± 0.03	0.23 ± 0.04
T/L	0.15 ± 0.04	0.19 ± 0.01	0.25 ± 0.07
T/B	0.51 ± 0.08	0.59 ± 0.06	0.71 ± 0.14
T/M	2.27 ± 0.53	2.20 ± 0.67	2.76 ± 0.82

The results were presented as mean ± SD (n = 9). Uptake is expressed in %ID/g tissue. Tumor/non-tumor ratios are unitless.

\* Radioactivity in blood was determined by ROI over heart.

T, tumor; K, Kidneys; L, Liver; B, Blood; M, Muscle.